Medicare, Eli Lilly and Zepbound

Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, reducing apnea events by 62.8%.
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli Lilly's drug Zepbound,
Onlymyhealth10d
FDA Approves Weight-Loss Drug Zepbound For Obstructive Sleep Apnea
FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).